clinical trial · NCT07463573
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.·phase3·recruiting·n = 466
Esophageal Squamous Cell Carcinoma (ESCC)QLC5508Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)
brief summary
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
started
Apr 20, 2026
primary completion
Jun 5, 2028
completion
Jul 5, 2029
last updated
Apr 24, 2026
official title
A Randomized, Open-Label, Multicenter Phase III Study of QLC5508 Versus Investigator's Choice Chemotherapy in Pretreated Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol